argenx SE
0QW0.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$50.67B
Close$
Share Statistics
| Market cap | $50.67 Billion |
|---|---|
| Enterprise Value | $47.18 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $21.07 |
| Beta | 0.53 |
| Outstanding Shares | 64,409,487 |
Return
| Return on Equity | 25.29% |
|---|---|
| Return on Assets | 21.22% |
| Return on Invested Capital | 25.00% |
Valuation & Multiples
| P/E Ratio | 29.58 |
|---|---|
| PEG | 12.23 |
| Price to Sales | 8.85 |
| Price to Book Ratio | 5.93 |
| Enterprise Value to Revenue | 8.34 |
| Enterprise Value to EBIT | 22.32 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$5.54
Average shareholder expectationRevenue Estimate
$1.26 B
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
$6.57
Average shareholder expectationRevenue Estimate
$1.25 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Argen X SE
1,599 employees
CEO: Tim Van Hauwermeiren argenx SE is a biotechnology firm dedicated to advancing innovative treatments for autoimmune conditions across key global markets, including the United States, several European nations (the Netherlands, Belgium, Switzerland, Germany, Fr...